StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Pre split low’s

<< Previous

Bullboard Posts

Next >>

Comment by IainCaimbeulon Jan 27, 2022 4:10pm

134 Views

Post# 34368456

RE:RE:RE:RE:RE:RE:Pre split low’s

Yer losing it bud.

Nailbiter1 wrote: Some of us "old timers" may have fkd things up a bit.
I had a big special box to carry my cajones in a few years ago.
Some of us used to call the Genenews billing dept to try and try to get a fix on numbers.
The CEO called me back instead of the billing clerk and told me to take
a long HARD suck of his ar... After he dipped it in maggotty butter.
Called me all kinds of names and hurt my feelings.
Now I wait for official numbers.

Jack rules like no other.

IainCaimbeul wrote: No, actually ballpark would have been fine.

I know I am not following the Stage retail shareholder narrative so that upsets the "old timers". But as we used to say in Cape Breton they can all take a long suck of my ar...

I do like Jack.

Nailbiter1 wrote: Were you expecting an accurate / precise number of Aristotle sales to date? Did you ask for a total per quarter or a month by month breakdown?

quote=IainCaimbeul]Good call LL, maybe Richard could convince James of the value of communication. Maybe even light a fire under his derriere.
Sent an email (non rude variety) to Rebecca 5 biz days ago asking about Aristotel sales, needless to say crickets.

LithLover wrote: The largest shareholder is now Health Clinics. I can't see them wanting a r/s given their acquisition was all in shares. The same for wanting more dilution through additional rounds of financing.

You would think the best scenario for them is to help drive revenue to improve the share price or failing that to garner enouih interest to obtain a buyout so they receive the $2 a share that was part of the agreement.

As the largest shareholder I can't see them just sitting back and allowing splits, dillution etc without pushing revenue or working on a buy out. Richard is now on the board.

Our mesely share count doesn't come close to what they hold and assuming the AVRT shares and UK shares get added thats a total of 12,400,000 + 8,000,000 +2,500,000 = 22,900,000.

A potential 23 million shares, I'm sure they want the share price to increase organically worse than us.

brad129 wrote: Seems like the reverse split has really achieved nothing, we are currently at the low prior to the split, let's all remember this when they want to do another one.